Clinical Trial Details
EORTC-26101
Back to Clinical Trials Database
Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma – (previously: Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma)
| Trial Status | All trial activities ended |
|---|---|
| Dates |
Date of activation: 07-Oct-2011 Date Step1 close: 07-Jan-2015 |
| Data management at EORTC | Yes |
| Design |
Phase 3 Randomized open label |
| Targeted Sample size | EORTC Groups: 592 - All Groups: 592 |
| Treatment | |
| Study Staff | |
| Type of cancer | |
| Participating groups | |
| Protocol summary | http://clinicaltrials.gov/study/NCT01290939 |
| NCT number | NCT01290939 |
| EudraCT | 2010-023218-30 |
